Weight Loss with Glutaric Aciduria Type 1 in South Africa

Glutaric aciduria type 1 (GA1) is an autosomal recessive organic aciduria caused by deficiency of glutaryl-CoA dehydrogenase (GCDH), a mitochondrial enzyme involved in the degradation of lysine, hydroxylysine, and tryptophan. Without GCDH, glutaryl-CoA accumulates and is converted to glutaric acid (GA) and 3-hydroxyglutaric acid (3-OH-GA), which are selectively neurotoxic to the striatum (putamen and caudate nucleus) — the brain region controlling voluntary movement.

The clinical course of GA1 has a characteristic pattern:

• Pre-crisis: Macrocephaly (enlarged head circumference) at birth or in infancy — a useful diagnostic clue; often asymptomatic
• Encephalopathic crisis: Typically between 6 months and 6 years of age, triggered by febrile illness, vaccination, or surgery; causes acute striatal injury
• Post-crisis: Dyskinetic/dystonic cerebral palsy — movement disorder ranging from mild to severe; may include choreoathetosis, opisthotonos, dystonic storms
• Older patients without crisis history: May remain relatively asymptomatic neurologically into adulthood, with ongoing subdural haematoma risk due to stretched bridging veins

In South Africa, GA1 is detected through expanded newborn screening programmes where available, and managed at metabolic centres. Key management centres include Red Cross War Memorial Children's Hospital, Charlotte Maxeke Johannesburg Academic Hospital, and Steve Biko Academic Hospital.

Why GA1 Makes Weight Management Uniquely Complex

1. Lysine and tryptophan restriction — the dietary foundation of GA1

GA1 dietary management targets the two main precursor amino acids:

• Lysine — the primary substrate; responsible for ~75% of glutaric acid production; found in high concentrations in meat, fish, poultry, dairy, eggs, and legumes
• Tryptophan — secondary substrate; found in protein-rich foods; also precursor to serotonin and niacin, adding nutritional complexity to restriction

GA1 patients follow a lysine-restricted, tryptophan-controlled diet supplemented with a lysine-free, tryptophan-reduced amino acid formula. This formula provides essential amino acids and energy without the substrates that generate toxic metabolites.

For weight management, this means:

• High-lysine foods (all meats, fish, dairy, eggs, legumes) are controlled — the same high-protein foods relied on for satiety and muscle preservation in standard weight-loss programmes
• Natural protein is therefore limited; most protein requirement comes from the amino acid supplement
• Total protein from natural food is typically 0.8–1.2 g/kg/day in adults

2. The striatal injury risk and catabolism

The striatum — damaged in GA1 crises — contains high concentrations of lysine-transporting cells and GCDH is relatively deficient here. During catabolism (starvation, illness, trauma, surgery), muscle protein breakdown releases lysine and tryptophan systemically, increasing substrate delivery to the brain and raising local glutaric acid concentrations.

Adults and older children with GA1 are generally past the highest-risk window for acute striatal injury (which is primarily before age 6), but the principle still applies:

• Catabolism raises circulating lysine and tryptophan from endogenous sources
• Concurrent illness + fasting during weight loss is a double metabolic stressor
• Even sub-crisis catabolism can worsen pre-existing movement disorder and neurological status

3. Movement disorder and its impact on exercise and calorie burning

GA1 patients who sustained striatal injury have varying degrees of dystonia, choreoathetosis, or dyskinesia. This profoundly affects:

• Basal metabolic rate: Dystonic muscle contraction (especially severe generalised dystonia) massively increases caloric expenditure — some patients are underweight due to uncontrolled dystonic calorie burn, not overweight
• Exercise tolerance and type: Voluntary coordinated exercise may be limited by movement disorder severity; hydrotherapy and supported exercise are often better options
• Caloric needs: May be significantly higher than predicted by standard BMI/weight equations — especially in patients with severe dystonia
• Oral feeding: Oromotor dysfunction and dysphagia may limit food intake; some patients are gastrostomy-fed

4. Subdural haematoma risk

GA1 causes macrocephaly with stretched bridging veins between the brain and the skull's dural lining. Even minor head trauma can cause subdural haematomas. Contact sports, activities with fall risk, or high-impact exercise should be assessed carefully — especially in patients with GA1 who have not had a crisis (and therefore may not have motor impairment to signal caution).

Safe Caloric Deficit for GA1

The Emergency Protocol: High-Carbohydrate Illness Management

All GA1 patients should have an emergency regimen — a high-carbohydrate, high-energy protocol to use during febrile illness, vomiting, or any state where normal eating is disrupted. This emergency regimen prioritises glucose delivery to suppress catabolism:

• Glucose polymer (Maxijul, Polycose) in drinks or feeds
• Suspension of natural protein temporarily (to reduce substrate load)
• Continuation of amino acid supplement for essential amino acids
• Hospital admission if vomiting prevents oral intake — IV glucose (10% dextrose) may be needed

During any weight-loss period, keep your emergency protocol letter accessible. Any illness that prevents eating for more than 4–6 hours should trigger the emergency regimen — not continued fasting.

Lysine Content of Common SA Foods

Exercise for GA1

Exercise recommendations must be completely individualised based on neurological status:

Patients with mild or no movement disorder

• Walking, cycling, swimming — moderate aerobic exercise well-suited
• Resistance training (moderate weights) — safe with cardiac clearance
• Avoid contact sports or activities with high fall/head injury risk (subdural risk)
• Wear a helmet for cycling and any activity with fall risk

Patients with moderate dystonia/dyskinesia

• Hydrotherapy — warm water reduces dystonic tone, allows movement not possible on land; excellent for GA1
• Supported stationary cycling
• Physiotherapy-guided exercise — tone management and maintaining range of motion
• Standing frames and supported positioning for those unable to ambulate

Patients with severe generalised dystonia

• Caloric management here is about adequate intake, not restriction — dystonic storms can burn 3 000–4 000+ kcal/day
• Exercise is managed by physiotherapy for comfort and contracture prevention
• Weight goals should focus on healthy weight for height, not weight loss

General exercise rules for all GA1 patients

• Always eat before exercise — fasted exercise is dangerous
• Carry glucose source (juice, glucose tablets) to every session
• Avoid exercise during febrile illness
• Wear a medical alert bracelet with GA1 and emergency protocol details
• Inform exercise facility/gym of your condition and what to do in an emergency

Monitoring During Weight Loss in GA1

• Plasma lysine and tryptophan — checked at metabolic clinic; ensure lysine is within target range
• Urine glutarylcarnitine / glutaric acid / 3-OH-glutaric acid — metabolic control markers
• Plasma acylcarnitine profile (C5DC — glutarylcarnitine) — GCDH deficiency marker
• Neurological status monitoring — any new or worsening movement symptoms need urgent metabolic review
• Body weight trend — target 0.25–0.5 kg/week loss maximum in appropriate patients
• Nutritional status — plasma albumin, iron, zinc, B12 (risk of deficiency on restricted diet)

South African Resources for GA1

• AIMDS — Association for Inherited Metabolic Disorders in South Africa — patient support network
• Metabolic dietitian at specialist centre for lysine/tryptophan tolerance calculation and amino acid supplement titration
• Lysine-free amino acid supplements (e.g., XLYS, TRY range) may require importation and Section 21 authorisation from SAHPRA
• Urine organic acid analysis (including glutaric acid) available at NHLS
• Plasma acylcarnitine (C5DC) available through NHLS Metabolic Biochemistry
• Genetic testing (GCDH mutation analysis) available at NHLS Molecular Pathology